Sonam Puri, MD

My clinical and research interest within thoracic oncology include clinical and translational research in small cell and EGFR mutation positive lung cancer.

Associations

• Thoracic Oncology
• Molecular Medicine Program

My research interests include 1. Designing and conducting clinical trials for novel targeted therapies and immunotherapies in lung cancer. Over the past five years, I have advanced my expertise as a clinical investigator in lung cancer, playing key roles in multiple clinical studies. A notable experience was my critical role in the "Osi + Ipi study," a phase 1 trial of Osimertinib and ipilimumab in EGFR-mutated NSCLC I was instrumental in-patient recruitment, regulatory coordination, and data analysis, leading to the successful completion of study accrual in February 2024. Building on this, I spearheaded an investigator-initiated phase 1 study integrating tumor-treating fields into therapy for locally advanced/stage III NSCLC. As the principal investigator at the Huntsman Cancer Institute (HCI), I led the project from protocol development to securing FDA IDE approval, with the trial activating in March 2024. I am now extending this work at MCC, continuing as the site PI while collaborating with translational and basic science teams to advance our understanding of lung cancer biology. 2. Engaging with biotechnology partners to explore new technologies to deepen our understanding of disease progression and improve prognostic accuracy in patients with lung cancer eg of research in this area include CNSide for CSF-derived tumor cells and FitBit® for prognosis assessment. 3. Improving our understanding of molecular Subtyping and innovative therapeutics for Small Cell Lung Cancer In addition to my work in NSCLC, I have a strong interest in SCLC. I have led multi-institutional collaborations with Dr. Owonikoko (University of Maryland), Dr. Oliver (Duke University), and Dr. Liu (Georgetown University), focusing on the molecular subtyping of high-grade neuroendocrine malignancies, including both lung and extrapulmonary small cell carcinoma. I have presented the data from these collaborations at prominent national and international meetings, including ASCO 2021 and ESMO 2022. These presentations were well-received, and publications based on this work are forthcoming, where I will serve as the first author. Furthermore, I have served as the site PI for three SCLC studies, including a trial with tarlatamab that recently received FDA approval for recurrent SCLC. This achievement underscores my ongoing commitment to advancing therapies for this challenging disease and highlights my proactive approach to driving innovation in lung cancer treatment.

Clinical Trial 22441
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination with Chemotherapy, in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Condition: Thoracic
Intervention: Alimta (Pemetrexed); ORIC-114 (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()
Status: Open

Clinical Trial 23420
A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Condition: Thoracic
Intervention: BHV-1510 (); Cemiplimab (); REGN2810 (Cemiplimab)
Status: Open

Clinical Trial 23535
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Amivantamab (); JNJ-61186372 (Amivantamab); JNJ-73841937 (Lazertinib); Lazertinib (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()
Status: Open

Clinical Trial 23580
A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)
Condition: Thoracic
Intervention: BH-30643 ()
Status: Open

Clinical Trial 23581
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Atezolizumab (Tecentriq); Durvalumab (); MEDI4736 (Durvalumab); Tarlatamab (AMG 757); YL201 ()
Status: Open

Clinical Trial 23582
A Phase II, multisite, open-label, single arm trial of BNT327 in combination with docetaxel in second-line stage IV non-small cell lung cancer (NSCLC) following chemoimmunotherapy
Condition: Thoracic
Intervention: BNT327 (); Taxotere (docetaxel); docetaxel ()
Status: Open

Clinical Trial 23584
A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined with Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Atezolizumab (Tecentriq); Durvalumab (); Iadademstat (); MEDI4736 (Durvalumab)
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol. 2025 Oct.9:e2500538. Pubmedid: 41166675.
• Ireland AS, Xie DA, Hawgood SB, Barbier MW, Zuo LY, Hanna BE, Lucas-Randolph S, Tyson DR, Witt BL, Govindan R, Dowlati A, Moser JC, Thomas A, Puri S, Rudin CM, Chan JM, Elliott A, Oliver TG. Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer. Nature. 2025 Nov.647(8088):257-267. Pubmedid: 40963028. Pmcid: PMC12589105.
• da Silva IP, Zimmer L, Blay JY, Maio M, Larkin J, Grimm MO, Puri S, Butler MO, Patel S, Thakkar PK, Long GV, Melero I. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO Open. 2025 Nov.10(11):105833. Pubmedid: 41202502. Pmcid: PMC12639429.
• Fenlon J, Van Bibber N, Mahlow J, Yamoah K, Soupir AC, Nguyen JV, Moran Segura C, Spivak AM, Knudsen BS, Zhou Q, Hu-Lieskovan S, Puri S, Zhang W, DeRose YS, Suneja G, Coghill AE. Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers. Cancer Epidemiol Biomarkers Prev. 2025 Jun.34(6):860-867. Pubmedid: 40183760. Pmcid: PMC12133412.
• Jo Y, Puri S, Haaland B, Coletta AM, Chipman JJ, Embrey K, Kerrigan KC, Patel SB, Moynahan K, Gumbleton M, Akerley WL. Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer. 2025 Jan.26(1):29-38. Pubmedid: 39572323.
• Sen T, Dotsu Y, Corbett V, Puri S, Sen U, Boyle TA, Mack P, Hirsch F, Aljumaily R, Naqash AR, Sukrithan V, Karim NA. Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies. Lancet Oncol. 2025 Jan.26(1):e13-e33. Pubmedid: 39756451.
• Coletta AM, Lee H, Puri S, Culleton S, Covington MF, Yap JT, Maslana KE, Haaland B, Akerley W. The Association Between Body Composition, Overall Survival, Treatment Decisions, and Patient-Reported Outcomes in Metastatic Non-Small-Cell Lung Cancer. Cancer Med. 2025 Jan.14(1):e70534. Pubmedid: 39764691.
• Kirtane K, Puri S, Chung CH. Durable Complete Response of a Delta-Like Ligand 3 Expressing Head and Neck Neuroendocrine Carcinoma to Tarlatamab. JCO Precis Oncol. 2025 Dec.9:e2500806. Pubmedid: 41370728.
• Zhang B, Alder L, Rosner S, Desai A, Cooper AJ, Yimer H, Bogdanska W, Naqash AR, Taylor A, Joshi U, Carlisle J, Champiat S, Altan M, Vega MF, Halm J, Manzano JG, Fenton G, Nie Y, Wang K, Parma M, Rudin CM, Chiang A, Byers LA, Gay CM, Puri S. A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS. Lung Cancer. 2025 Dec.211:108870. Pubmedid: 41371100.
• Owen DH, Halmos B, Puri S, Qin A, Ismaila N, Abu Rous F, Alluri K, Freeman-Daily J, Malhotra N, Marrone KA, Bazhenova L. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1. J Clin Oncol. 2025 Aug.43(24):e45-e58. Pubmedid: 40674687.
• Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, Goldschmidt J, Khrizman P, Proto C, Patel S, Puri S, Liu SV, Massarelli E, Williamson D, Schwickart M, Scheffold C, Andrianova S, Felip E. Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clin Res Rep. 2024 Oct.5(10):100666. Pubmedid: 39318387. Pmcid: PMC11421317.
• Ireland AS, Hawgood SB, Xie DA, Barbier MW, Lucas-Randolph S, Tyson DR, Zuo LY, Witt BL, Govindan R, Dowlati A, Moser JC, Puri S, Rudin CM, Chan JM, Elliott A, Oliver TG. Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer. bioRxiv. 2024 Nov. Pubmedid: 39605338. Pmcid: PMC11601426.
• Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M. A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. Clin Cancer Res. 2024 Nov.30(22):5042-5052. Pubmedid: 39287821. Pmcid: PMC11565168.
• Wang X, Lee H, Haaland B, Kerrigan K, Puri S, Akerley W, Shen J. A matching-based machine learning approach to estimating optimal dynamic treatment regimes with time-to-event outcomes. Stat Methods Med Res. 2024 May.33(5):794-806. Pubmedid: 38502008.
• Owen DH, Jaiyesimi IA, Leighl NB, Ismaila N, Florez N, Puri S, Schenk EL, Schneider BJ, Patel JD. Therapy for Stage IV Non-Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights. JCO Oncol Pract. 2024 Jul.20(7):893-898. Pubmedid: 38588478.
• Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan.30(1):265-270. Pubmedid: 38177853. Pmcid: PMC11135132.
• Puri S, Malani R, Chalmers A, Kerrigan K, Patel SB, Monynahan K, Cannon L, Blouw B, Akerley W. Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSideTM. Neurooncol Adv. 2024 Jan.6(1):vdad150. Pubmedid: 38196737. Pmcid: PMC10776200.
• Bazhenova L, Ismaila N, Abu Rous F, Alluri K, Freeman-Daily J, Halmos B, Malhotra N, Marrone KA, Puri S, Qin A, Leighl NB. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. J Clin Oncol. 2024 Dec.42(36):e72-e86. Pubmedid: 39531596.
• Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, Puri S, Naqash AR. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024 Aug.21(8):610-627. Pubmedid: 38965396.
• Bodor JN, Patel JD, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, Ross EA, Litwin S, Clapper ML, Treat J. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clin Lung Cancer. 2023 Nov.24(7):e242-e246. Pubmedid: 37451930. Pmcid: PMC11476834.
• Sama S, Kerrigan K, Sinnott JA, Puri S, Akerley W, Haaland B, Patel S. Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. Cancer Treat Res Commun. 2023 May.35:100686. Pubmedid: 36736060.
• Smith JT, Puri S, Akerley W. Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib. Clin Lung Cancer. 2023 Jun.24(4):360-361. Pubmedid: 36935243.
• Cannon-Albright LA, Teerlink CC, Stevens J, Facelli JC, Carr SR, Allen-Brady K, Puri S, Bailey-Wilson JE, Musolf AM, Akerley W. A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall-cell lung cancer. Int J Cancer. 2023 Jul.153(2):364-372. Pubmedid: 36916144. Pmcid: PMC10182245.
• El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023 Jul.41(21):3712-3723. Pubmedid: 37192435. Pmcid: PMC10351941.
• Burns L, Hsu CY, Whisenant JG, Marmarelis ME, Presley CJ, Reckamp KL, Khan H, Jo Fidler M, Bestvina CM, Brahmer J, Puri S, Patel JD, Halmos B, Hirsch FR, Liu SV, Costa DB, Goldberg SB, Feldman LE, Mamdani H, Puc M, Mansfield AS, Islam N, Scilla KA, Garassino MC, Horn L, Peters S, Wakelee HA, Charlot M, Tapan U. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). Lung Cancer. 2023 Dec.186:107423. Pubmedid: 37995456.
• Puri S, Saltos AN, Gray JE. Race-inclusive and equitable access to immune checkpoint inhibitor therapy: What are the biggest hurdles?. Cancer. 2023 Dec.129(23):3692-3693. Pubmedid: 37728029.
• Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer. 2023 Aug.11(8). Pubmedid: 37586768. Pmcid: PMC10432623.
• Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 May.17(5):661-674. Pubmedid: 35121086. Pmcid: PMC8804493.
• Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S. A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep. 2022 Mar.3(3):100280. Pubmedid: 35243411. Pmcid: PMC8861643.
• Kerrigan K, Puri S. Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. Curr Oncol Rep. 2022 Jan.24(1):113-123. Pubmedid: 35060001.
• Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B. Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel). 2022 Jan.14(3). Pubmedid: 35158958. Pmcid: PMC8833771.
• Higgins KA, Puri S, Gray JE. Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Feb.40(6):576-585. Pubmedid: 34985931.
• Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2021 Oct.160:92-98. Pubmedid: 34482103. Pmcid: PMC8853639.
• Florou V, Puri S, Garrido-Laguna I, Wilky BA. Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Ann Transl Med. 2021 Jun.9(12):1035. Pubmedid: 34277835. Pmcid: PMC8267318.
• Naqash AR, Kihn-Alarcón AJ, Stavraka C, Kerrigan K, Maleki Vareki S, Pinato DJ, Puri S. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Ann Transl Med. 2021 Jun.9(12):1034. Pubmedid: 34277834. Pmcid: PMC8267312.
• Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med. 2021 Jun.9(12):1040. Pubmedid: 34277840. Pmcid: PMC8267267.
• Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W. Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer. 2021 Jul.22(4):260-267.e2. Pubmedid: 33678584.
• Kulkarni AA, Naqash AR, Puri S, Dienstmann R. Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer?. JCO Precis Oncol. 2021 Feb.5. Pubmedid: 34109281. Pmcid: PMC8177880.
• Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021 Dec.12(25):2449-2458. Pubmedid: 34917263. Pmcid: PMC8664394.
• Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Dec.19(12):1441-1464. Pubmedid: 34902832. Pmcid: PMC10203822.
• Puri S, Lok BH, Leighl N, Gray JE. Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer. Front Oncol. 2020 Nov.10:1783. Pubmedid: 33282719. Pmcid: PMC7705219.
• Puri S, Saltos A, Perez B, Le X, Gray JE. Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep. 2020 Mar.22(4):31. Pubmedid: 32140986.
• Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero D, Qiao Y, Huang X, Tarapcsák S, Devarakonda S, Chalishazar MD, Gertz J, Moser JC, Marth G, Puri S, Witt BL, Spike BT, Oliver TG. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell. 2020 Jul.38(1):60-78.e12. Pubmedid: 32473656. Pmcid: PMC7393942.
• Puri S, Shafique M. Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs Context. 2020 Jan.9. Pubmedid: 32158484. Pmcid: PMC7048109.
• Puri S, Holle LM, Forouhar FA, Clement JM. Subcutaneous metastasis from recurrent basaloid squamous cell carcinoma of the esophagus. J Oncol Pharm Pract. 2019 Mar.25(2):492-496. Pubmedid: 29078709.
• Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2019 Feb.60(2):309-316. Pubmedid: 29963932.
• Puri S, Shafique M, Gray JE. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. CURR TREAT OPTION ON. 2018 Jun.19(8):39. Pubmedid: 29931587.
• Le X, Puri S, Negrao MV, Nilsson M, Robichaux JP, Boyle TA, Hicks JK, Lovinger K, Roarty EB, Rinsurongkawong W, Tang M, Sun H, Elamin YY, Lacerda L, Lewis J, Lee JJ, Roth JA, Swisher SG, Zhang J, William WN, Glisson BS, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res. 2018 Dec.24(24):6195-6203. Pubmedid: 30228210. Pmcid: PMC6295279.
• Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, Lin HY, Hoogland AI, Gonzalez BD, Nelson AM, Kinney AY, Fischer SM, Li D, Jacobsen PB, McLeod HL, Jim HSL. Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer. 2018 Aug.26(8):2911-2918. Pubmedid: 29546524. Pmcid: PMC6200138.
• Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Rev Respir Med. 2017 Oct.11(10):791-805. Pubmedid: 28786318.
• Puri S, Markowitz J. The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. Ann Res Hosp. 2017 May.1. Pubmedid: 31460494. Pmcid: PMC6711479.
• Puri R, Puri S, Rajani A. Letter by Puri et al Regarding Article, "Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control". Circulation. 2017 May.135(19):e1039-e1040. Pubmedid: 28483838.
• Gupta T, Parikh K, Puri S, Agrawal S, Agrawal N, Sharma D, DeLorenzo L. The forgotten disease: Bilateral lemierre's disease with mycotic aneurysm of the vertebral artery. Am J Case Rep. 2014 May.15:230-234. Pubmedid: 24883173. Pmcid: PMC4038640.
• Phatak P, Khanagavi J, Aronow WS, Puri S, Yusuf Y, Puccio C. Pericardial synovial sarcoma: challenges in diagnosis and management. F1000Res. 2014 Jan.3:15. Pubmedid: 24715974. Pmcid: PMC3954165.

• Title: S2503: A Randomized Phase II Study of Atezolizumab and JBI-802 Versus Investigator’s Choice of Standard of Care for Previously Treated Extensive Stage Small Cell Lung Cancer
  Award Number: S2503
  Sponsor: HOPE FOUNDATION
  Gray, J. (), Puri, S. (PD/PI)